What the business is, and whether it's a good one at a fair price.
Manufactures specialty chemicals and pharmaceutical intermediates for global pharmaceutical customers across three verticals. The contrast media vertical supplies gadolinium and iodinated contrast media intermediates to formulation customers; FY26 revenue grew 23% YoY on new product launches, with Q4 alone surging 91% YoY to INR 193 crore. PI/API revenue fell 35% YoY to INR 298 crore as customers worked through inventory, but management says destocking is complete and FY27 should exceed the FY25 peak of ~INR 460 crore. A third vertical in high-intensity sweeteners is under validation, with trial shipments expected over coming quarters. Manufacturing runs from Ambernath and Mahad; Mahad Unit 3 backward integration for a contrast media raw material begins production in H2 FY27 to improve margins via supply chain self-reliance. New capacity at Vizag (a multi-year greenfield project) and a peptide-focused R&D centre in Hyderabad are being added; raw materials account for 41% of revenue and the company closed FY26 debt-free with INR 400 crore in liquid assets.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from BLUE JET HEALTHCARE LTD's filed financials and exchange disclosures
BLUE JET HEALTHCARE LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol BLUEJET.
Yes. Over the trailing twelve months BLUE JET HEALTHCARE LTD reported a net profit of ₹235 Cr on revenue of ₹886 Cr.
Yes. The dividend yield is 0.21% at the current price. It paid out 8% of its profit as dividend in FY26.
Effectively yes. It holds ₹61 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, BLUE JET HEALTHCARE LTD ranks 116 of 169 in Pharmaceuticals — cheaper than 32% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session BLUE JET HEALTHCARE LTD moves 1.54% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by BLUE JET HEALTHCARE LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
